# Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice

## TL;DR

This study shows that switching to faricimab in a treat-and-extend regimen for neovascular AMD increases treatment intervals without worsening vision in real-world patients.

## Contribution

The study provides real-world evidence of faricimab's effectiveness in patients previously treated with anti-VEGF agents.

## Key findings

- Switching to faricimab significantly increased treatment intervals in neovascular AMD patients.
- Best-corrected visual acuity remained stable during the follow-up period.
- No serious adverse events were reported with faricimab treatment.

## Abstract

To evaluate the clinical outcomes of the switch to faricimab in a treat-and-extend (T&E) regimen patients with neovascular age-related macular degeneration (nAMD).

This prospective cohort study included consecutive patients with nAMD who had previously been treated with anti-VEGF agents in a T&E regimen, with treatment intervals (TI) that could not be extended beyond 12 weeks, and a minimum follow-up of 24 weeks. These patients were switched to faricimab therapy in a T&E regimen for at least 6 months. The primary endpoint was the TI between intravitreal injections (IVIs), and the secondary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to the last follow-up visit (LFUV).

A total of 225 eyes from 188 patients were included, with a mean age of 79.6 ± 7.4 years. Previous anti-VEGF treatments included ranibizumab (n = 34), aflibercept (n = 144), brolucizumab (n = 6), and bevacizumab (n = 41). TI1 (5.9 ± 2.0 weeks) matched the prior treatment interval. Significant increases in treatment intervals were observed at subsequent time points (TI2: 8.2 ± 3.2 weeks, TI3: 10.1 ± 3.9 weeks, TI4: 10.7 ± 4.3 weeks, TI5: 9.9 ± 4.0 weeks, and TI6: 8.5 ± 4.4 weeks; p < 0.001). BCVA remained stable, going from 0.41 ± 0.23 to 0.43 ± 0.24 (p = 0.0112). The mean number of injections was 5.9 ± 1.9, with a mean follow-up duration of 51.4 ± 11.8 weeks.

The switch to faricimab in a T&E regimen significantly increased treatment intervals maintaining BCVA in patients with nAMD under other anti-VEGF treatments. No serious adverse events were reported. Longer follow-up is needed to confirm these results.

The online version contains supplementary material available at 10.1186/s40942-025-00776-0.

Results from clinical trials have shown the safety and efficacy of faricimab for AMD patients

Real-life patient often differ from those from clinical trials so results can seldom be extrapolated

This study provides results of faricimab in pretreated neovascular AMD patients in real-world clinical practice

Different factors (age, initial BCVA and number of previous intravitreal injections) may play a role on the efficacy of the drug in refractory cases

The online version contains supplementary material available at 10.1186/s40942-025-00776-0.